Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Irinotecan and Apatinib in Extensive Stage SCLC
NCT06749691Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nanoliposomal irinotecan and Rivoceranib in small cell lung cancer (SCLC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Progression-Free-Survival rate at 6 months. Started Dec 2024; status: recruiting.
02
Drugs
nanoliposomal irinotecanRivoceranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06749691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06749691.